Literature DB >> 14670770

The clinical and health economic burden of respiratory syncytial virus disease among children under 2 years of age in a defined geographical area.

S A Deshpande1, V Northern.   

Abstract

AIMS: To describe the clinical and health economic impact of respiratory syncytial virus (RSV) disease in children under 2 years of age.
METHODS: Hospitalised children less than 2 years of age with a respiratory illness were studied over three consecutive RSV seasons (1996-99).
RESULTS: The rates (per 1000 infants under 1 year of age) of hospitalisations from bronchiolitis and RSV illness were 30.8 and 24.4 respectively. The rates of death, intensive care admission, and need for ventilatory assistance during RSV related hospitalisation were 0.2%, 2.7%, and 1.5% respectively. From a cohort of 841 preterm infants, 6.3% had an RSV related hospitalisation during the study period, with the rate rising to 9.2% among those who were either born before 36 weeks gestation and were under 6 months of age at the onset of the RSV seasons, or were less than 2 years of age with chronic lung disease needing home oxygen therapy. Eight of 25 children on home oxygen therapy had RSV related rehospitalisation. Need for assisted ventilation during the neonatal period and discharge home on oxygen therapy were significantly associated with the risk of subsequent RSV related hospitalisation in preterm infants less than 6 months of age. The direct health authority cost of all RSV hospitalisations was pound 542 203, while the currently recommended immunoprophylaxis for the high risk infants would have cost pound 652 960.
CONCLUSIONS: Preterm infants receiving assisted ventilation and those on home oxygen therapy are particularly at risk of RSV related hospitalisation. Serious adverse outcomes are however uncommon even among these high risk infants.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14670770      PMCID: PMC1719378          DOI: 10.1136/adc.88.12.1065

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  14 in total

1.  Economic evaluation and clinical trials: size matters.

Authors:  A Briggs
Journal:  BMJ       Date:  2000-12-02

Review 2.  Respiratory syncytial virus and parainfluenza virus.

Authors:  C B Hall
Journal:  N Engl J Med       Date:  2001-06-21       Impact factor: 91.245

3.  Home oxygen status and rehospitalisation and primary care requirements of infants with chronic lung disease.

Authors:  A Greenough; J Alexander; S Burgess; P A J Chetcuti; S Cox; W Lenney; F Turnbull; N J Shaw; A Woods; J Boorman; S Coles; J Turner
Journal:  Arch Dis Child       Date:  2002-01       Impact factor: 3.791

4.  Respiratory syncytial virus infection in high risk infants and the potential impact of prophylaxis in a United Kingdom cohort.

Authors:  S J Clark; M W Beresford; N V Subhedar; N J Shaw
Journal:  Arch Dis Child       Date:  2000-10       Impact factor: 3.791

5.  Rehospitalization for respiratory syncytial virus among premature infants.

Authors:  S Joffe; G J Escobar; S B Black; M A Armstrong; T A Lieu
Journal:  Pediatrics       Date:  1999-10       Impact factor: 7.124

6.  Hospitalisation for RSV infection in ex-preterm infants-implications for use of RSV immune globulin.

Authors:  M Thomas; A Bedford-Russell; M Sharland
Journal:  Arch Dis Child       Date:  2000-08       Impact factor: 3.791

7.  Bronchiolitis-associated hospitalizations among US children, 1980-1996.

Authors:  D K Shay; R C Holman; R D Newman; L L Liu; J W Stout; L J Anderson
Journal:  JAMA       Date:  1999-10-20       Impact factor: 56.272

8.  Deprivation and bronchiolitis.

Authors:  N Spencer; S Logan; S Scholey; S Gentle
Journal:  Arch Dis Child       Date:  1996-01       Impact factor: 3.791

9.  Epidemiology of respiratory viral infection among paediatric inpatients over a six-year period in north-east England.

Authors:  A J Martin; P S Gardner; J McQuillin
Journal:  Lancet       Date:  1978-11-11       Impact factor: 79.321

10.  Improved outcome of respiratory syncytial virus infection in a high-risk hospitalized population of Canadian children. Pediatric Investigators Collaborative Network on Infections in Canada.

Authors:  L Navas; E Wang; V de Carvalho; J Robinson
Journal:  J Pediatr       Date:  1992-09       Impact factor: 4.406

View more
  53 in total

1.  Economic impact of community-acquired and nosocomial lower respiratory tract infections in young children in Germany.

Authors:  Birgit Ehlken; Gabriele Ihorst; Barbara Lippert; Angela Rohwedder; Gudula Petersen; Martin Schumacher; Johannes Forster
Journal:  Eur J Pediatr       Date:  2005-06-18       Impact factor: 3.183

Review 2.  Acute bronchiolitis.

Authors:  Andrew Bush; Anne H Thomson
Journal:  BMJ       Date:  2007-11-17

Review 3.  Management of acute viral bronchiolitis in children: Evidence beyond guidelines.

Authors:  Shaikh Mohammed Iqbal
Journal:  Sudan J Paediatr       Date:  2012

4.  Optimal level of nasal continuous positive airway pressure in severe viral bronchiolitis.

Authors:  Sandrine Essouri; Philippe Durand; Laurent Chevret; Laurent Balu; Denis Devictor; Brigitte Fauroux; Pierre Tissières
Journal:  Intensive Care Med       Date:  2011-10-13       Impact factor: 17.440

Review 5.  Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis.

Authors:  Harish Nair; D James Nokes; Bradford D Gessner; Mukesh Dherani; Shabir A Madhi; Rosalyn J Singleton; Katherine L O'Brien; Anna Roca; Peter F Wright; Nigel Bruce; Aruna Chandran; Evropi Theodoratou; Agustinus Sutanto; Endang R Sedyaningsih; Mwanajuma Ngama; Patrick K Munywoki; Cissy Kartasasmita; Eric A F Simões; Igor Rudan; Martin W Weber; Harry Campbell
Journal:  Lancet       Date:  2010-05-01       Impact factor: 79.321

6.  Modern approaches to understanding stress and disease susceptibility: A review with special emphasis on respiratory disease.

Authors:  Palok Aich; Andrew A Potter; Philip J Griebel
Journal:  Int J Gen Med       Date:  2009-07-30

7.  Nasal continuous positive airway pressure decreases respiratory muscles overload in young infants with severe acute viral bronchiolitis.

Authors:  Gilles Cambonie; Christophe Milési; Samir Jaber; Francis Amsallem; Eric Barbotte; Jean-Charles Picaud; Stefan Matecki
Journal:  Intensive Care Med       Date:  2008-07-08       Impact factor: 17.440

8.  Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults.

Authors:  Christopher A Green; Elisa Scarselli; Charles J Sande; Amber J Thompson; Catherine M de Lara; Kathryn S Taylor; Kathryn Haworth; Mariarosaria Del Sorbo; Brian Angus; Loredana Siani; Stefania Di Marco; Cinzia Traboni; Antonella Folgori; Stefano Colloca; Stefania Capone; Alessandra Vitelli; Riccardo Cortese; Paul Klenerman; Alfredo Nicosia; Andrew J Pollard
Journal:  Sci Transl Med       Date:  2015-08-12       Impact factor: 17.956

Review 9.  Respiratory syncytial virus--a comprehensive review.

Authors:  Andrea T Borchers; Christopher Chang; M Eric Gershwin; Laurel J Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2013-12       Impact factor: 8.667

10.  Palivizumab: a review of its use in the protection of high risk infants against respiratory syncytial virus (RSV).

Authors:  Joseph M Geskey; Neal J Thomas; Gretchen L Brummel
Journal:  Biologics       Date:  2007-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.